Treatment of acute uncomplicated falciparum malaria with artemether-lumefantrine in nonimmune populations: a safety, efficacy, and pharmacokinetic study.
about
The clinical efficacy of artemether/lumefantrine (Coartem)Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient dataImpact of the large-scale deployment of artemether/lumefantrine on the malaria disease burden in Africa: case studies of South Africa, Zambia and EthiopiaSafety and efficacy of pyronaridine-artesunate in uncomplicated acute malaria: an integrated analysis of individual patient data from six randomized clinical trials.Malaria in infants below six months of age: retrospective surveillance of hospital admission records in Blantyre, Malawi.Update on the efficacy, effectiveness and safety of artemether-lumefantrine combination therapy for treatment of uncomplicated malaria.Treatment of asymptomatic carriers with artemether-lumefantrine: an opportunity to reduce the burden of malaria?A review of the effects of artemether-lumefantrine on gametocyte carriage and disease transmissionPharmacokinetics of artemether and dihydroartemisinin in healthy Pakistani male volunteers treated with artemether-lumefantrineDesbutyl-lumefantrine is a metabolite of lumefantrine with potent in vitro antimalarial activity that may influence artemether-lumefantrine treatment outcome.Artemether-lumefantrine compared to atovaquone-proguanil as a treatment for uncomplicated Plasmodium falciparum malaria in travelers.Community screening and treatment of asymptomatic carriers of Plasmodium falciparum with artemether-lumefantrine to reduce malaria disease burden: a modelling and simulation analysis.Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implicationsPopulation pharmacokinetics of artemether, lumefantrine, and their respective metabolites in Papua New Guinean children with uncomplicated malaria.Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients.Artemether-Lumefantrine Combination Therapy for Treatment of Uncomplicated Malaria: The Potential for Complex Interactions with Antiretroviral Drugs in HIV-Infected Individuals.Intravenous pharmacokinetics, oral bioavailability, dose proportionality and in situ permeability of anti-malarial lumefantrine in rats.Surveillance for the safety and effectiveness of artemether-lumefantrine in patients with uncomplicated Plasmodium falciparum malaria in the USA: a descriptive analysisLumefantrine and Desbutyl-Lumefantrine Population Pharmacokinetic-Pharmacodynamic Relationships in Pregnant Women with Uncomplicated Plasmodium falciparum Malaria on the Thailand-Myanmar Border.Therapy of uncomplicated falciparum malaria in Europe: MALTHER - a prospective observational multicentre study.Broadly reactive antibodies specific for Plasmodium falciparum MSP-1(19) are associated with the protection of naturally exposed children against infection.Population pharmacokinetics of Artemether and dihydroartemisinin in pregnant women with uncomplicated Plasmodium falciparum malaria in UgandaConcomitant efavirenz reduces pharmacokinetic exposure to the antimalarial drug artemether-lumefantrine in healthy volunteers.Safety of falciparum malaria diagnostic strategy based on rapid diagnostic tests in returning travellers and migrants: a retrospective study.Impact of using artemisinin-based combination therapy (ACT) in the treatment of uncomplicated malaria from Plasmodium falciparum in a non-endemic zone.Pharmacokinetic properties of artemether, dihydroartemisinin, lumefantrine, and quinine in pregnant women with uncomplicated plasmodium falciparum malaria in Uganda.Atovaquone-proguanil in the treatment of imported uncomplicated Plasmodium falciparum malaria: a prospective observational study of 553 cases.Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria.Population Pharmacokinetics of Lumefantrine in Pregnant and Nonpregnant Women With Uncomplicated Plasmodium falciparum Malaria in Uganda.Safety profile of Coartem: the evidence base.Cardiac complication after experimental human malaria infection: a case report.Efficacy and safety of artemether-lumefantrine in the treatment of acute, uncomplicated Plasmodium falciparum malaria: a pooled analysisSuccessful oral therapy for severe falciparum malaria: the World Health Organization criteria revisited.K13-propeller Alleles, Mdr1 Polymorphism, and Drug Effectiveness at Day 3 after Artemether-lumefantrine Treatment for Plasmodium falciparum Malaria in Colombia, 2014-2015.Malaria management-progress made and challenges still to face.Detection of Malaria Parasites After Treatment in Travelers: A 12-months Longitudinal Study and Statistical Modelling Analysis.Antimalarial Resistance Unlikely To Explain U.K. Artemether-Lumefantrine Failures.Assessment of Clinical Pharmacokinetic Drug-Drug Interaction of Antimalarial Drugs α/β-Arteether and Sulfadoxine-Pyrimethamine.
P2860
Q21034141-6235283B-E7E7-4431-B9D7-F7FF24051096Q26783646-152A3DA2-BE84-41F3-8479-9AE8FA4D1495Q27497242-9CFFB7E0-F507-494C-BD93-591200323B22Q30592761-B9B01D44-34A7-450C-9008-FA9D811DDF30Q33587448-B94AFE5B-DB77-4287-BE67-9CC71C46B8DDQ33635019-9CD87C0F-06CB-47F2-A861-838EA312B3C0Q33670134-2D7D3EBF-FECB-49E5-8A81-B941B492574AQ34020818-1388B169-6A44-49F2-89A2-B10C3386B138Q34221884-02AA60C5-7B1E-47FD-AC01-7B1009CEBC40Q34737444-C64B4A9C-2BA6-4954-A3EC-33CD1BD636BAQ35140545-6C482899-1BAC-4C75-97E0-E129B7A91ACDQ35179184-AC68455F-899E-4A25-8C6F-89D046D75490Q35286119-102812AB-AADD-4C1F-9012-2D4355BD2A27Q35363704-A798499A-89FC-422F-B509-8E01B39B38B8Q35598594-30178231-357E-4FEE-8346-3C130AB56B06Q35692270-A6DE1296-2281-42D2-90DA-FB719BA3FF3DQ35834996-0E209A95-487E-4B58-B31B-5378F32300BBQ36069930-E0F19D34-14B2-4DA2-BC9C-F5E98B9C4AD7Q36075976-B42CC064-23BA-4FEB-AD99-AA7FCEDA29DDQ36334960-C6797D28-E233-4638-9FE7-6F43397D08EFQ36411599-B7C1E334-5013-443C-BFDF-B0DB60549D6DQ36411652-8E9B0012-468A-4281-939D-4557CA2E4907Q36438820-39B7AA36-104C-47A6-B652-FD55454FDC9EQ36483387-75D4B379-C61F-404E-AC36-024575501D26Q37059579-34FCBBFA-1E47-497C-B3AC-E2FC827157D0Q37263818-FB3CAD5B-8EA8-4AEA-B37B-619AC298C510Q37317559-9D33C5DD-277B-4180-9053-49D2F8B86ECFQ37333155-769A6F07-BF20-4D48-A511-1E7AD3BBEF0FQ37366055-26C22555-9E60-49D7-BA75-71560D24B60CQ37383298-61B2B508-EB85-43AE-9F6F-B188CBB00634Q37477948-5CBE51E9-0882-49A8-8C1F-98FD259D14E7Q38895510-F4A5A1EA-AB9C-406E-B5B7-437C640B7906Q41436125-B76AB1A7-2B98-4112-84D4-51B3EE40212BQ41911890-6EE10F8E-439F-4FA8-9EA8-98C354FD7F36Q42581302-A0F4E619-A951-4673-95CC-EFDD6B010E52Q46280172-5AFA722E-CE16-4E2A-A846-84D6E0EA0E20Q47998548-5B072CF1-7021-46C4-8359-A75278180A88Q47998942-372203AD-7F9C-4ACD-8A76-9A8851359520
P2860
Treatment of acute uncomplicated falciparum malaria with artemether-lumefantrine in nonimmune populations: a safety, efficacy, and pharmacokinetic study.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Treatment of acute uncomplicat ...... cy, and pharmacokinetic study.
@en
Treatment of acute uncomplicat ...... cy, and pharmacokinetic study.
@nl
type
label
Treatment of acute uncomplicat ...... cy, and pharmacokinetic study.
@en
Treatment of acute uncomplicat ...... cy, and pharmacokinetic study.
@nl
prefLabel
Treatment of acute uncomplicat ...... cy, and pharmacokinetic study.
@en
Treatment of acute uncomplicat ...... cy, and pharmacokinetic study.
@nl
P2093
P1476
Treatment of acute uncomplicat ...... acy, and pharmacokinetic study
@en
P2093
Blaise Genton
Christoph Hatz
Francois Bricaire
Frederick Gay
Gerd-Dieter Burchard
Gilbert Lefèvre
Hans Dieter Nothdurft
Kim Andriano
Louis Loutan
Patricia Ibarra De Palacios
P304
P356
10.4269/AJTMH.2008.78.241
P407
P577
2008-02-01T00:00:00Z